Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
暂无分享,去创建一个
H. Kantarjian | J. Cortes | L. Medeiros | J. Khoury | R. Luthra | S. Loghavi | Z. Gong | L. Zheng | W. Wang | G. Tang | W. Yang | S. Hu | Shimin Hu | Lan Zheng | Wei Wang
[1] B. George,et al. Frequency of rare BCR‐ABL1 fusion transcripts in chronic myeloid leukemia patients , 2017, International journal of laboratory hematology.
[2] L. Medeiros,et al. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia , 2016, Blood Cancer Journal.
[3] H. Kantarjian,et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.
[4] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[5] Z. Estrov,et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. , 2016, Blood.
[6] M. Ladetto,et al. Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib , 2014 .
[7] Martin C. Müller,et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib , 2014, Haematologica.
[8] H. Kantarjian,et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.
[9] H. Kantarjian,et al. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib , 2011, Cancer.
[10] M. Baccarani,et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[12] R. Reinhardt,et al. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. , 2008, Leukemia research.
[13] R. Kawaguchi,et al. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). , 2002, Internal medicine.
[14] S. Ohtake. Chronic myelogenous leukemia with p190BCR-ABL expression: the missing link with monocytosis. , 2002, Internal medicine.
[15] M. Hur,et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia , 2002, Annals of Hematology.
[16] R. Kawaguchi,et al. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). , 2002, Internal medicine.
[17] E. Morra,et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. , 2000, European journal of cancer.